ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Pfizer and BioNTech to develop mRNA flu vaccines

by Ryan Cross
August 17, 2018 | APPEARED IN VOLUME 96, ISSUE 33

 

Another big drug firm is joining the mRNA therapy field. Pfizer is paying Bio­NTech $120 million to develop mRNA flu vaccines and offering up to $305 million more in potential milestone payments. Moderna Therapeutics has already tested its own mRNA flu vaccine in a Phase I study. mRNA vaccines have also found an audience with nonprofit groups interested in making vaccines more cheaply and quickly during future pandemics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment